Barclays Has Lowered Expectations for Sarepta Therapeutics (NASDAQ:SRPT) Stock Price
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its price objective cut by investment analysts at Barclays from $89.00 to $29.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. Barclays‘s target price suggests a potential upside of 39.62% from the stock’s current […]
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its price objective cut by investment analysts at Barclays from $89.00 to $29.00 in a note issued to investors on Tuesday,Benzinga reports. The brokerage presently has an “overweight” rating on the biotechnology company’s stock. Barclays‘s target price suggests a potential upside of 39.62% from the stock’s current […]
